The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables
AUTOR(ES)
Fernandez-Gomez, J, Madero, R, Solsona, E, Unda, M, Martinez-Piñeiro, L, Ojea, A, Portillo, J, Montesinos, M, Gonzalez, M, Pertusa, C, Rodriguez-Molina, J, Camacho, JE, Rabadan, M, Astobieta, A, Isorna, S, Muntañola, P, Gimeno, A, Blas, M, Martinez-Piñeiro, JA
FONTE
International braz j urol
DATA DE PUBLICAÇÃO
2011-10
RESUMO
Documentos Relacionados
- An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer
- External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1
- Diminished efficacy of bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer
- The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasıve bladder cancer: a prospective randomized study
- Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
